Trial Profile
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Romosozumab (Primary) ; Denosumab
- Indications Fracture; Postmenopausal osteoporosis; Vertebral fracture
- Focus Registrational; Therapeutic Use
- Acronyms FRAME
- Sponsors Amgen; Astellas Pharma; UCB
- 01 Dec 2022 Results of post hoc analysis assessing efficacy and safety of Romosozumab in European patients enrolled in FRAME trial and extension study, published in the Osteoporosis International.
- 14 Nov 2022 Results of effect of romosozumab in postmenopausal women with knee osteoarthritis, presented at the ACR Convergence 2022
- 01 Aug 2022 Results of post-hoc analysis of two studies (FRAME and ARCH) assessing efficacy and safety of romosozumab in postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease, published in the Journal of Bone and Mineral Research.